arrow_back Back to App

New Rules for FDA Contractors: Transparency and Conflict of Interest Prevention

This act introduces new rules for companies working with the Food and Drug Administration (FDA). Its goal is to increase transparency and prevent situations where consulting firms might have conflicting interests, influencing decisions about drugs and medical devices. This helps ensure that FDA decisions are made without hidden influences, benefiting public trust.
Key points
Companies contracting with the FDA must continuously disclose any potential conflicts of interest, including those involving their personnel and subcontractors.
The FDA will publish information about any waivers granted regarding conflicts of interest, increasing public oversight.
Restrictions are placed on consulting firms to prevent their employees from simultaneously working for the FDA and for companies developing or manufacturing drugs or medical devices, aiming to prevent undue influence.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_8828
Sponsor: Rep. Kuster, Ann M. [D-NH-2]
Process start date: 2022-09-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

FDA Ethics Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_8828.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-09-14.

What are the main provisions?

Key points include:

  • Companies contracting with the FDA must continuously disclose any potential conflicts of interest, including those involving their personnel and subcontractors.
  • The FDA will publish information about any waivers granted regarding conflicts of interest, increasing public oversight.
  • Restrictions are placed on consulting firms to prevent their employees from simultaneously working for the FDA and for companies developing or manufacturing drugs or medical devices, aiming to prevent undue influence.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Kuster, Ann M. [D-NH-2].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Courts and Law